The Safety, Pharmacokinetics, and Antiviral Activity of ABI-4334, A Novel Next-Generation Hepatitis B Capsid Assembly Modulator.
Edward J Gane, Christian Schwabe, Nelli Ghicavii et al.
✦ AI-curated · Sources linked
In 30 seconds
Two randomized Phase 1 studies assessed ABI-4334, a hepatitis B capsid assembly modulator, in healthy volunteers and participants with chronic hepatitis B (cHBV). Study 101 evaluated safety and pharmacokinetics in healthy volunteers; Study 102 examined these outcomes and antiviral activity in participants with cHBV. Across the studies, 54 healthy volunteers and 20 participants with cHBV were included. ABI-4334 was well tolerated, with no treatment-emergent serious adverse events or adverse events leading to discontinuation. In cHBV participants, HBV DNA declines were observed across doses, and pgRNA reductions occurred in those with detectable baseline pgRNA.
Key findings
- Across both studies, 54 healthy volunteers and 20 participants with cHBV received study treatment or placebo.
- No treatment-emergent serious adverse events or adverse events leading to study discontinuation were reported.
- After multiple dosing in cHBV participants, steady-state mean plasma half-life ranged from 17.5 to 27.5 h.
- HBV DNA declines occurred in HBeAg-positive (n = 3) and HBeAg-negative (n = 13) participants; pgRNA reductions were seen when baseline pgRNA was detectable.
Why it matters
Capsid assembly modulators are being explored as potential components of treatment strategies for chronic hepatitis B. These early studies provide initial human safety, pharmacokinetic, and antiviral-activity data for ABI-4334, including observed changes in HBV DNA and pgRNA. The findings help inform further clinical evaluation but do not establish sustained antiviral benefit or clinical efficacy.
What to keep in mind
These were Phase 1 studies with small participant groups and short-term assessment; antiviral findings are preliminary.